Trial Profile
Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Alunacedase alfa (Primary)
- Indications COVID-19 respiratory infection
- Focus Therapeutic Use
- Acronyms APN01-COVID-19
- Sponsors Apeiron Biologics
- 12 Mar 2021 Primary endpoint has been met. (Cause of death or invasive mechanical ventilation), according to an Apeiron Biologics Media Release.
- 12 Mar 2021 Results published in the Apeiron Biologics Media Release
- 21 Jan 2021 Status changed from recruiting to completed.